Happy Thursday, Zingernation! I may have made some dumb decisions last weekend (naturally) but by far the worst was deciding to go to Costco at 2 PM on a Saturday. I went to buy paper towels and laundry detergent. I wound up buying the stock instead.

It was so packed that it took me more than 15 minutes to find a parking spot. By the time I got a cart, ate 26 different samples and got my obligatory $1.50 hot dog and soda combo, I had been there for an hour and still hadn’t put any items in my basket.

Not sure how Costco looks on an analyst’s report, but you just can’t beat those intangibles.

Today’s Price Action:

$SPY: +.75%
$QQQ: +1.60%
$DIA: +.01%

Also, check out the company that is revolutionizing how we treat pancreatic cancer.

And, did someone forward you this email? Click here to subscribe to this Benzinga newsletter and more.

TODAY’S MOST VOLATILE STOCKS

TODAY’S TOP STORY

Apple In AI Arms Race, Looks To Revamp Lagging Mac Sales: Report

Briefly: Apple traded higher on the heels of a new overhaul plan for its sluggish Mac line.

What Happened: The laptop and desktop innovator released its first Macs with M3 chips just five months ago, but it’s already gearing up to produce the next generation.

What Now: This time, the technology is designed to highlight artificial intelligence. The new chip — the M4 processor — will come in at least three main varieties and be incorporated into every Mac model.

Why It Matters: The move is part of an effort to boost Mac sales. In the fourth quarter of 2023, sales hovered at around $7.6 billion, down 34% from $11.5 billion a year earlier. Mac revenue for all of 2023 was $29.4 billion, down from $40.2 billion in 2022.

Click here to read the full breakdown.

PRESENTED BY THERIVA BIOLOGICS

Theriva Biologics’s Novel Treatment Aims To Disrupt The $3 Billion Market For Treating Pancreatic Cancer

Pancreatic cancer has, unfortunately, been in the news lately due to the rising rates of early-onset cancer, especially in young people. Pancreatic cancer, which has a 12% five-year survival rate,  is expected to become the second-highest cause of cancer-associated deaths in 2030 in the U.S. In 2024 it is projected that 64,440 Americans will be diagnosed with pancreatic cancer. 

Theriva Biologics (NYSE American: TOVX) is a biotech company that is looking to use adenoviruses to help treat pancreatic cancer. Theriva Biologics' lead product candidate, VCN-01, is a uniquely modified human adenovirus designed for systemic delivery to treat different types of cancer.  Currently, the company is conducting a phase 2b clinical trial of its VCN-01 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. 

Click here to read more!

FIVE MOVERS

Sunrun shares dropped today after mixed PPI data added to uncertainty regarding the Fed’s plans to cut rates later this year.

Nike shares hit a sprint today, closing up more than 3% after a BofA Securities analyst upgraded the stock and raised the price target.

Netflix shares closed higher in today’s session as investors appeared to take bullish positions on the streaming giant ahead of its upcoming earnings.

Delta Airlines shares soared higher today, closing higher after another BofA price target upgrade. Here’s why the analyst is bullish.

Amazon stock edged higher in today’s session after CEO Andy Jassy said the company is committed to cost-cutting measures while investing in AI.

ONE TRADE IDEA FOR TOMORROW

E.l.f. Beauty Advances Digital Strategy With App For Apple's Vision Pro, CEO Says Business Has 'Never Been Stronger'

Briefly: e.l.f. Beauty is blowing up on social media. Here’s how they did it.

So Basically: CEO Tarang Amin discussed the company's digital strategy with Jim Cramer on CNBC’s Mad Money.

So Then: Amin told Cramer that e.l.f Beauty’s digital business was up by more than 100% last quarter, which he attributed to the company’s willingness to try new things. e.l.f. was one of the first beauty brands to embrace TikTok, has its own Twitch channel and offers a popular brand experience on Roblox.

So What? "As a digitally native brand, we're constantly testing and learning," Amin said on the show. "We're going to constantly test and learn on new frontiers and delight our community."

What Next: The company's newest digital experience is the "your best e.l.f." app for the Apple Vision Pro headset, which it describes as a "spatial experience" where users engage with "playful, inspirational environments that contextualize an assortment of 3D e.l.f. products."

Click here to read more.

PRESENTED BY THERIVA BIOLOGICS

Theriva Biologics’s Novel Treatment Aims To Disrupt The $3 Billion Market For Treating Pancreatic Cancer

Pancreatic cancer has, unfortunately, been in the news lately due to the rising rates of early-onset cancer, especially in young people. Pancreatic cancer, which has a 12% five-year survival rate,  is expected to become the second-highest cause of cancer-associated deaths in 2030 in the U.S. In 2024 it is projected that 64,440 Americans will be diagnosed with pancreatic cancer. 

Theriva Biologics (NYSE American: TOVX) is a biotech company that is looking to use adenoviruses to help treat pancreatic cancer. Theriva Biologics' lead product candidate, VCN-01, is a uniquely modified human adenovirus designed for systemic delivery to treat different types of cancer.  Currently, the company is conducting a phase 2b clinical trial of its VCN-01 in combination with standard-of-care chemotherapy for first-line metastatic pancreatic cancer. 

Click here to read more!